Tumour angiogenesis regulation by the miR-200 family

Chad V. Pecot; Rajesha Rupaimoole; Da Yang; Rehan Akbani; Cristina Ivan; Chunhua Lu; Sherry Wu; Hee Dong Han; Maitri Y. Shah; Cristian Rodriguez-Aguayo; Justin Bottsford-Miller; Yuexin Liu; Sang Bae Kim; Anna Unruh; Vianey Gonzalez-Villasana; Li Huang; Behrouz Zand; Myrthala Moreno-Smith; Lingegowda S. Mangala; Morgan Taylor; Heather J. Dalton; Vasudha Sehgal; Yunfei Wen; Yu Kang; Keith A. Baggerly; Ju Seog Lee; Prahlad T. Ram; Murali K. Ravoori; Vikas Kundra; Xinna Zhang; Rouba Ali-Fehmi; Ana Maria Gonzalez-Angulo; Pierre P. Massion; George A. Calin; Gabriel Lopez-Berestein; Wei Zhang; Anil K. Sood

doi:10.1038/ncomms3427

Tumour angiogenesis regulation by the miR-200 family

Chad V. Pecot, Rajesha Rupaimoole, Da Yang, Rehan Akbani, Cristina Ivan, Chunhua Lu, Sherry Wu, Hee Dong Han, Maitri Y. Shah, Cristian Rodriguez-Aguayo, Justin Bottsford-Miller, Yuexin Liu, Sang Bae Kim, Anna Unruh, Vianey Gonzalez-Villasana, Li Huang, Behrouz Zand, Myrthala Moreno-Smith, Lingegowda S. Mangala, Morgan TaylorHeather J. Dalton, Vasudha Sehgal, Yunfei Wen, Yu Kang, Keith A. Baggerly, Ju Seog Lee, Prahlad T. Ram, Murali K. Ravoori, Vikas Kundra, Xinna Zhang, Rouba Ali-Fehmi, Ana Maria Gonzalez-Angulo, Pierre P. Massion, George A. Calin, Gabriel Lopez-Berestein, Wei Zhang, Anil K. Sood

Research output: Contribution to journal › Article › peer-review

340 Scopus citations

Abstract

The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.

Original language	English (US)
Article number	2427
Journal	Nature communications
Volume	4
DOIs	https://doi.org/10.1038/ncomms3427
State	Published - Sep 10 2013

ASJC Scopus subject areas

General Chemistry
General Biochemistry, Genetics and Molecular Biology
General Physics and Astronomy

MD Anderson CCSG core facilities

Bioinformatics Shared Resource
Research Animal Support Facility
Small Animal Imaging Facility

Access to Document

10.1038/ncomms3427

Cite this

Pecot, C. V., Rupaimoole, R., Yang, D., Akbani, R., Ivan, C., Lu, C., Wu, S., Han, H. D., Shah, M. Y., Rodriguez-Aguayo, C., Bottsford-Miller, J., Liu, Y., Kim, S. B., Unruh, A., Gonzalez-Villasana, V., Huang, L., Zand, B., Moreno-Smith, M., Mangala, L. S., ... Sood, A. K. (2013). Tumour angiogenesis regulation by the miR-200 family. Nature communications, 4, Article 2427. https://doi.org/10.1038/ncomms3427

Pecot, CV, Rupaimoole, R, Yang, D, Akbani, R, Ivan, C, Lu, C, Wu, S, Han, HD, Shah, MY, Rodriguez-Aguayo, C, Bottsford-Miller, J, Liu, Y, Kim, SB, Unruh, A, Gonzalez-Villasana, V, Huang, L, Zand, B, Moreno-Smith, M, Mangala, LS, Taylor, M, Dalton, HJ, Sehgal, V, Wen, Y, Kang, Y, Baggerly, KA, Lee, JS, Ram, PT, Ravoori, MK, Kundra, V, Zhang, X, Ali-Fehmi, R, Gonzalez-Angulo, AM, Massion, PP, Calin, GA , Lopez-Berestein, G, Zhang, W & Sood, AK 2013, 'Tumour angiogenesis regulation by the miR-200 family', Nature communications, vol. 4, 2427. https://doi.org/10.1038/ncomms3427

@article{df0c3f54cc2d4a0c9a9b856129e1bc4f,

title = "Tumour angiogenesis regulation by the miR-200 family",

abstract = "The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.",

author = "Pecot, {Chad V.} and Rajesha Rupaimoole and Da Yang and Rehan Akbani and Cristina Ivan and Chunhua Lu and Sherry Wu and Han, {Hee Dong} and Shah, {Maitri Y.} and Cristian Rodriguez-Aguayo and Justin Bottsford-Miller and Yuexin Liu and Kim, {Sang Bae} and Anna Unruh and Vianey Gonzalez-Villasana and Li Huang and Behrouz Zand and Myrthala Moreno-Smith and Mangala, {Lingegowda S.} and Morgan Taylor and Dalton, {Heather J.} and Vasudha Sehgal and Yunfei Wen and Yu Kang and Baggerly, {Keith A.} and Lee, {Ju Seog} and Ram, {Prahlad T.} and Ravoori, {Murali K.} and Vikas Kundra and Xinna Zhang and Rouba Ali-Fehmi and Gonzalez-Angulo, {Ana Maria} and Massion, {Pierre P.} and Calin, {George A.} and Gabriel Lopez-Berestein and Wei Zhang and Sood, {Anil K.}",

year = "2013",

month = sep,

day = "10",

doi = "10.1038/ncomms3427",

language = "English (US)",

volume = "4",

journal = "Nature communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Tumour angiogenesis regulation by the miR-200 family

AU - Pecot, Chad V.

AU - Rupaimoole, Rajesha

AU - Yang, Da

AU - Akbani, Rehan

AU - Ivan, Cristina

AU - Lu, Chunhua

AU - Wu, Sherry

AU - Han, Hee Dong

AU - Shah, Maitri Y.

AU - Rodriguez-Aguayo, Cristian

AU - Bottsford-Miller, Justin

AU - Liu, Yuexin

AU - Kim, Sang Bae

AU - Unruh, Anna

AU - Gonzalez-Villasana, Vianey

AU - Huang, Li

AU - Zand, Behrouz

AU - Moreno-Smith, Myrthala

AU - Mangala, Lingegowda S.

AU - Taylor, Morgan

AU - Dalton, Heather J.

AU - Sehgal, Vasudha

AU - Wen, Yunfei

AU - Kang, Yu

AU - Baggerly, Keith A.

AU - Lee, Ju Seog

AU - Ram, Prahlad T.

AU - Ravoori, Murali K.

AU - Kundra, Vikas

AU - Zhang, Xinna

AU - Ali-Fehmi, Rouba

AU - Gonzalez-Angulo, Ana Maria

AU - Massion, Pierre P.

AU - Calin, George A.

AU - Lopez-Berestein, Gabriel

AU - Zhang, Wei

AU - Sood, Anil K.

PY - 2013/9/10

Y1 - 2013/9/10

N2 - The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.

AB - The miR-200 family is well known to inhibit the epithelial-mesenchymal transition, suggesting it may therapeutically inhibit metastatic biology. However, conflicting reports regarding the role of miR-200 in suppressing or promoting metastasis in different cancer types have left unanswered questions. Here we demonstrate a difference in clinical outcome based on miR-200's role in blocking tumour angiogenesis. We demonstrate that miR-200 inhibits angiogenesis through direct and indirect mechanisms by targeting interleukin-8 and CXCL1 secreted by the tumour endothelial and cancer cells. Using several experimental models, we demonstrate the therapeutic potential of miR-200 delivery in ovarian, lung, renal and basal-like breast cancers by inhibiting angiogenesis. Delivery of miR-200 members into the tumour endothelium resulted in marked reductions in metastasis and angiogenesis, and induced vascular normalization. The role of miR-200 in blocking cancer angiogenesis in a cancer-dependent context defines its utility as a potential therapeutic agent.

UR - http://www.scopus.com/inward/record.url?scp=84887251722&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887251722&partnerID=8YFLogxK

U2 - 10.1038/ncomms3427

DO - 10.1038/ncomms3427

M3 - Article

C2 - 24018975

AN - SCOPUS:84887251722

SN - 2041-1723

VL - 4

JO - Nature communications

JF - Nature communications

M1 - 2427

ER -

Tumour angiogenesis regulation by the miR-200 family

Abstract

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this